RxDoctor Payments Data

Travis Chandler, NP

Primary Care · Burley, IDNPI 1861927634

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for primary care clinicians in ID, where the typical reported total is $390.

$294in general payments, 2019–2025

Across 17 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$60
  • Neurocrine Biosciences, Inc.$39
  • Nestle Healthcare Nutrition Inc.$37
  • AstraZeneca$34
  • Otsuka America Pharmaceutical, Inc.$25
  • Dexcom, Inc.$24
  • plus $75 from 5 others

What the payments were for

  • Food & beverage$294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$294 in reported general payments places this provider in the 45th percentile of 48 primary care providers in Idaho.

See all primary care providers in Idaho

Medicare billing

Part B allowed, 2024
$41,936
Medicare patients
189
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$81,811
TrulicityDulaglutide33$41,926
OzempicSemaglutide27$29,169
XareltoRivaroxaban47$26,127
MounjaroTirzepatide17$25,743
JardianceEmpagliflozin46$21,931
MyrbetriqMirabegron42$12,590
NeuproRotigotine13$11,619
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,026
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$7,921
Spiriva RespimatTiotropium Bromide14$7,812
Fentanyl79$7,664
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,504
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen287$5,407
Pregabalin131$5,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$60$29,16927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 48 primary care providers in Idaho.

Other primary care in Burley

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →